Business Wire

Avaya Transforms Portugal’s Emergency Services Communications Systems to Prepare for eCall

Jaa

Avaya Holdings Corp. (NYSE: AVYA) today announced that Portugal’s emergency services have adopted its suite of communication solutions to transform their existing systems in preparation for eCall, the next-generation automated vehicle aid system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606005478/en/

(Photo: Business Wire)

(Photo: Business Wire)

A life-saving innovation that is mandatory in all new passenger-vehicle types approved for sale in the European Union from April 2018, eCall allows telemetry data to be sent from a vehicle to emergency services when an accident occurs, providing accurate incident location and other vital information that dispatchers can use to send help much faster and more effectively to help save lives. With 25,670 fatalities in 2016 and over 135,000 serious injuries on EU roads and motorways in 2014, according to the European Transport Safety Council’s Road Safety Performance Index, eCall is estimated to reduce emergency response time by 40% in built-up areas and 50% in the countryside, saving as many as 2,500 lives and over EUR 130 billion in costs to society each year.

As a result, emergency services across Portugal have been running tests to demonstrate readiness to receive and respond to these new automated calls. As the global market leader in contact center solutions, Avaya was selected because of its ecosystem and open platform structure, enabling integration across a variety of different systems. The solutions deployed include: the creation of a new center in Porto to increase resiliency and geographic redundancy; a complete refresh of the existing emergency service data center in Lisbon; and an upgrade of the existing communication environment, including a subsequent integration into its dispatching application.

Markus Bornheim, Consulting Sales Engineer for Public Safety and Emergency Services at Avaya, and Vice Chair of the European Emergency Number Association (EENA) Technical Committee, said:

“Emergency Services communications require intricate coordination between a number of different channels, from voice calls, to calls from mobiles and now to eCall. It’s important to deliver a solution that can accommodate both present and future needs without putting undue pressure on those working in call centres or on the front line. Avaya’s eCall solution was designed to integrate with existing systems and provide a clear platform for further development. We are pleased to see our work achieve a strong result for Portugal, and look forward to extending this further elsewhere in Europe.”

Implementation of these solutions was carried out by Avaya’s local integration partner PAPTI/DECUNIFY, which worked with core tech provider Oecon and software developer Engelbart Software to adapt and modify the existing application development platform and allow integration with Portugal’s emergency services. As a result, Portugal’s 112 services can now receive, interpret and respond to messages sent through eCall; as well as integrate other eCall-associated technologies and similar third-party services for motorcycles, heavy goods vehicles, car manufacturers, assistance companies and automobile clubs. With Avaya’s support, solutions and architecture, Portugal achieved full preparation for the onset of eCall, in advance of the EU conformity assessment.

Colonel Vitor Judicibus, Head of the Critical Communications Multidisciplinary Team at the General Secretariat of Internal Administration (Secretaria-geral da Administração Interna) said:

“eCall is a major milestone for the European automotive and safety communities, with next-generation technology being widely deployed to help people and save lives. Providing Portugal’s dispatchers and emergency services call centre workers with the tools they need to incorporate eCall is essential to achieving the aims of this initiative. We are pleased that the Portuguese 112 service has been upgraded to fully respond to eCall, while also becoming faster, more reliable, and future-fit.”

Francisco Gomes, Deputy Secretary General for Technologies of the Ministry of Home Affairs (Secretaria-geral da Administração Interna) said:

“According to Nikola Tesla ‘Science is but a perversion of itself unless it has as its ultimate goal the betterment of humanity.’ I think the same about technology, and eCall is one of the best recent examples of a major improvement in Europe for emergency reaction. The overall purpose of being more efficient on preserving human life after traffic accidents will progress immensely with the introduction of eCall. Our Ministry tech teams and our partners together, made possible for Portugal to be fully ready to do the best in emergency situations.”

About Avaya

Avaya is a global leader in digital communications software, services and devices for businesses of all sizes. Our open, intelligent and customizable solutions for contact centers and unified communications offer the flexibility of Cloud, on-premises and hybrid deployments. Avaya shapes intelligent connections and creates seamless communication experiences for our customers, and their customers. Our professional planning, support and management services teams help optimize solutions, for highly reliable and efficient deployments. Avaya Holdings Corp. is traded on the NYSE under the ticker AVYA. For more information, please visit www.avaya.com.

Cautionary Note Regarding Forward-Looking Statements

This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," “our vision,” "plan," "potential," "preliminary," "predict," "should," "will," or “would” or the negative thereof or other variations thereof or comparable terminology and include, but are not limited to, expected cash savings and statements about expected growth and growth strategies, future investments and new technologies,. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Registration Statement on Form 10 filed with the Securities and Exchange Commission, may cause its actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. For a further list and description of such risks and uncertainties, please refer to the Company’s filings with the SEC that are available at www.sec.gov . The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this report may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Source: Avaya Newsroom

Follow Avaya on Twitter, Facebook, YouTube, LinkedIn and Flickr

Contact information

Avaya
Iman Ghorayeb, +971-4-404-8275
ighorayeb@avaya.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00Tiedote

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05Tiedote

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth16.8.2018 02:40Tiedote

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy16.8.2018 01:37Tiedote

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

QConnect – Markkinoiden älykkäin, erittäin kompakti ja lujatekoinen viestintälaite15.8.2018 23:23Tiedote

Quake Global, Inc. (QUAKE), yksi maailman johtavista IoT-markkinoiden toimittajista, julkaisi QConnect™, uuden sukupolven kehittyneen telematiikkalaitteen. Äärimmäisen kompakti QConnect integroituu kiinteisiin ja liikkuviin omaisuuksiin niiden seuraamiseksi, valvomiseksi ja hallitsemiseksi reaaliajassa mistä ja milloin tahansa. Laite tarjoaa useita pitkälle kehitettyjä langattomia kommunikaatiovaihtoehtoja, mukaan lukien LTE/2G/3G, kaksitaajuus-Wi-Fi, Bluetooth/BLE, V2X ja satelliitti. Laite on suunniteltu vastaamaan moniin eri vaatimuksiin yksinkertaisista ja edullisista seurantasovelluksista aina korkean suorituskyvyn monikanavaisiin videon suoratoistosovelluksiin. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180815005706/fi/ Quake Global’s new QConnect, the most intelligent, global, ultra-compact and rugged communication device available (Photo: Business Wire) QConnect tarjoaa joustavuutta sen ainutlaatuisilla sovell

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 20:43Tiedote

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme